Integra LifeSciences Holdings Stock Market Outlook
| IART Stock | USD 13.56 -0.44 -3.14% |
This sentiment measure is descriptive rather than personalized advice and should be used with other evidence before acting on it. About 56% of recent sentiment around Integra LifeSciences has been mildly defensive over the recent sample. Taken on its own, that leaves the current sentiment reading for Integra LifeSciences Holdings close to neutral currently.
Investor Comfort Level
PanicConfidence
44 · Impartial
Elasticity to Hype and News Sentiment
Tracking Integra LifeSciences Holdings moderately positive news sentiment (67%) is particularly informative when headlines and price behavior start diverging. Cross-checking that reading with earnings momentum and price action helps confirm whether the narrative is running ahead of or behind the business.
Given a 90-day horizon, with a moderate risk tolerance, the model output for Integra LifeSciences Holdings is 'Strong Buy'. Our automated recommendation for Integra LifeSciences is built from quantitative evidence and fundamental indicators. The analysis combines quantitative signals with investor-specific risk parameters. The recommendation evaluates return potential against downside risk within defined investment parameters. Complementing automated signals with independent research strengthens the broad analytical foundation.
Integra |
Run Integra LifeSciences Outlook Model
Our Integra outlook engine provides a data-driven supplement to the analyst consensus on Integra LifeSciences Holdings. Macroaxis has no vested interest in Integra LifeSciences Holdings or any other instrument analyzed here. Multiple quantitative inputs drive the Integra LifeSciences' signal across different market conditions. Combining algorithmic signals with independent analysis supports more informed decisions.
How This Model Works
The recommendation output for Integra LifeSciences is a model-based view that converts the selected horizon and risk profile into a standardized reading of the current evidence.
- Inputs - valuation signals, price behavior, volatility, liquidity, sentiment, and analyst coverage when available
- Current setup - Three Months with a risk setting described as I am an average risk taker
- Limits - the model does not account for taxes, outside holdings, concentration constraints, or investor-specific mandates
Use the output as structured decision support and pair it with your own research, portfolio context, and any professional advice you rely on.
Time Horizon
Risk Tolerance
Strong Buy
Market Performance | Moderate | Details | |
Volatility | Low | Details | |
Current Valuation | Below Model Estimate | Details | |
Odds Of Distress | Moderate | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Integra LifeSciences' current outlook reflects mixed signals, where negative margins limit earnings-based valuation support, while risk metrics have not deteriorated further. The model's 'Strong Buy' signal reflects this balance across quantitative inputs rather than a directional bias. Over the selected time horizon, Integra LifeSciences shows Risk Adjusted Performance of 0.1059, Jensen Alpha of 0.4099, and Total Risk Alpha of 0.3972, which collectively support the constructive outlook.The quantitative analytical reading for Integra LifeSciences blends historical performance patterns with current market conditions and the analyst and expert consensus to frame the risk-reward profile. For additional context on this small-cap stock in the Health Care sector, review the full set of Integra LifeSciences reported fundamentals, including the relationship between the total debt ttm and trailing beta. Integra LifeSciences reports a price to earnings ttm of 26.94 X. Its market performance and financial distress probability provide additional context.
Recent Events and Market Context
The events below reflect recent headlines associated with Integra LifeSciences. Not all items directly affect the outlook โ they are included to show the broader information environment that can shape sentiment and trading behavior.
Returns Distribution Density
Plotting Integra LifeSciences' daily returns in a distribution reveals the day-to-day behavior of Integra LifeSciences. It shows how returns are grouped around the average and how often large swings occur. Value At Risk and Upside Potential quantify both the risk and the reward. Value At Risk shows the worst-case boundary and Upside Potential shows the best-case boundary.
| Mean Return | 0.43 | Value At Risk | -4.81 | Potential Upside | 5.48 | Standard Deviation | 4.24 |
Return Density |
| Distribution |
Risk management for Integra LifeSciences depends on quantifying the frequency and magnitude of extreme moves. The distribution chart below makes that clear for Integra LifeSciences. Portfolio managers weigh the trade-offs across risk-return profiles. Return distribution analysis highlights the frequency and magnitude of extreme price moves in Integra LifeSciences.
Top Institutional Investors
At small-cap scale, institutional coverage and secondary-market liquidity are typically well established. The holder split in Integra LifeSciences Holdings separates passive index allocation from active institutional positioning. The business currently sits in the Health Care sector and the Health Care Equipment & Services industry. At that level of institutional ownership, fund flows and rebalancing cycles drive most of the float.
| Shares | Charles Schwab Investment Management Inc | 2025-12-31 | 1.6 M | The Goldman Sachs Group Inc | 2025-12-31 | 1.4 M | Wellington Management Company Llp | 2025-12-31 | 1.4 M | J. Goldman & Co Lp | 2025-12-31 | 1.2 M | Systematic Financial Management Lp | 2025-12-31 | 1.1 M | Invenomic Capital Management, Lp | 2025-12-31 | 1.1 M | Quantinno Capital Management Lp | 2025-12-31 | 842.1 K | Bank Of America Corp | 2025-12-31 | 825.1 K | Glenmede Trust Co Na | 2025-12-31 | 772.9 K | Blackrock Inc | 2025-12-31 | 10.3 M | Rubric Capital Management Lp | 2025-12-31 | 7.8 M |
Key Drivers of Volatility and Market Exposure
Market risk ties Integra LifeSciences to macro cycles, whereas company or sector-specific developments represent independent drivers. Volatility metrics help measure this balance. Integra LifeSciences Holdings's financial profile includes a Downside Deviation of 3.39, a Mean Deviation of 2.66, and an Option Implied Volatility of 1.39.
α | Alpha over Dow Jones | 0.41 | |
β | Beta against Dow Jones | 2.07 | |
σ | Overall volatility | 4.32 | |
Ir | Information ratio | 0.1 |
Fundamentals Vs Peers
Integra LifeSciences is measured here against stocks with similar revenue scale, margin profile, and capital structure. The comparison below reveals whether Integra LifeSciences generates superior or inferior returns relative to similar stocks. Divergence between Integra LifeSciences' valuation multiples and its peer group flags either mispricing or a structural difference in quality. Direct comparison with similar stocks converts Integra LifeSciences's standalone financial data into an actionable relative signal.
| Better Than Average | Worse Than Average | Compare Integra LifeSciences to competition |
Note: Disposition of 848 shares by Mojdeh Poul of Integra Life Sciences subject to Rule 16 b-3 [view details]
Market Momentum
Integra LifeSciences Holdings momentum reading - RSI 65 (mildly bullish), beta 2.074 (high-beta) - helps distinguish trend continuation from fading conviction. That elevated sensitivity means momentum signals carry amplified risk on reversals.
| Rate Of Daily Change | 0.97 | |||
| Day Median Price | 13.56 | |||
| Day Typical Price | 13.56 | |||
| Price Action Indicator | -0.22 | |||
| Period Momentum Indicator | -0.44 | |||
| Relative Strength Index | 65.46 |
Current Target Price Consensus
Integra's target price is built from the average of all analyst forecasts we collect. Analyst performance can only be meaningfully measured through historical attribution analysis. The Integra LifeSciences' target price data below warrants integration with other forecasting methods for a complete picture. A multi-method strategy that includes technical analysis and sentiment evaluation strengthens Integra LifeSciences' assessment.
| 12 | Hold |
The standard cadence for Integra analyst updates is quarterly. Alongside each rating, analysts provide a target price reflecting their intrinsic value estimate for the stock. The analytical process involves reviewing Integra LifeSciences's financial filings and listening to conference calls. The combination of financial analysis and management access supports well-informed Integra recommendations.
Exposure ValuationIntegra LifeSciences Target Price Projection
The market currently values Integra LifeSciences at 13.56, while analysts project a target of 15.67. The market price shows where Integra LifeSciences Holdings trades today; the target shows where analysts expect the stock to go. The greater the spread between these prices, the stronger the incentive for investors to act. The spread between Integra LifeSciences' current price and target helps assess potential opportunity.Current Price
Integra LifeSciences Market Quote on 8th of May 2026
Target Price
Analyst Consensus On Integra LifeSciences Target Price
Integra LifeSciences Analyst Ratings
Integra LifeSciences draws a Hold consensus from the 12 analysts tracking it. Sentiment is leaning bearish, with 3 rate it favorably. Across the board, leaning bearish sentiment dominates Integra LifeSciences' analyst landscape. The chart below tracks how this breakdown has changed.Analyst Consensus Breakdown
Average Consensus Estimates
Recommendation Framework, Assumptions & Editorial Oversight
The model output for Integra LifeSciences reflects the current horizon and risk settings, refreshes as underlying data changes, and is intended to organize evidence rather than replace investor judgment. Current model inputs for Integra LifeSciences include P/E of 26.94, ROE of -39.9%. External analyst coverage is currently summarized as Hold across 12 analysts, but it is treated here as a secondary reference input rather than a stand-alone recommendation. Published target-price assumptions may also be reviewed when available, but they can change quickly as analyst models are revised. 
Integra LifeSciences Holdings metrics draw on periodic company reporting and market reference feeds, standardized for cross-period comparison. The model combines valuation, price behavior, volatility, and sentiment into a standardized quantitative view.
Editorial Review & Methodology Oversight
Role: Member of Macroaxis Editorial Board
Finance background: Gabriel is a young entrepreneur and writes predominantly on the business, technology, and finance sector. He likes to analyze different equity instruments across a wide range of industries focusing primarily on consumer products and evolving technologies.
Oversight scope: Reviews recommendation-framework framing, source assumptions, and disclosure language.